US Osteoarthritis Market Summary

As per Market Research Future analysis, the US osteoarthritis market Size was estimated at 895.6 USD Million in 2024. The US osteoarthritis market is projected to grow from 977.28 USD Million in 2025 to 2339.22 USD Million by 2035, exhibiting a compound annual growth rate (CAGR) of 9.1% during the forecast period 2025 - 2035

Key Market Trends & Highlights

The US osteoarthritis market is experiencing a transformative shift towards innovative and patient-focused treatment options.

The market is witnessing a rise in non-pharmacological treatments, reflecting a broader trend towards holistic care.
Technological innovations in treatment are enhancing the efficacy and accessibility of osteoarthritis management.
Patient-centric care is becoming increasingly prioritized, aligning treatment approaches with individual patient needs and preferences.
Key market drivers include the aging population and rising healthcare expenditure, which are significantly influencing market dynamics.

Market Size & Forecast

2024 Market Size	895.6 (USD Million)
2035 Market Size	2339.22 (USD Million)
CAGR (2025 - 2035)	9.12%

Major Players

Johnson & Johnson (US), Pfizer Inc. (US), Boehringer Ingelheim (DE), Novartis AG (CH), AbbVie Inc. (US), Amgen Inc. (US), Sanofi (FR), GlaxoSmithKline (GB), Eli Lilly and Company (US)

Our Impact

Enabled $4.3B Revenue Impact for Fortune 500 and Leading Multinationals

Partnering with 2000+ Global Organizations Each Year

30K+ Citations by Top-Tier Firms in the Industry

US Osteoarthritis Market Trends

The osteoarthritis market is currently experiencing notable transformations driven by various factors. The increasing prevalence of osteoarthritis among the aging population in the US is a primary catalyst for growth. As individuals age, the likelihood of developing this degenerative joint disease rises, leading to a heightened demand for effective treatment options. Furthermore, advancements in medical technology and pharmaceuticals are contributing to the development of innovative therapies, which may enhance patient outcomes and improve quality of life. This evolving landscape suggests a shift towards more personalized and targeted treatment approaches, potentially reshaping the therapeutic options available in the market. In addition to demographic changes, there is a growing emphasis on preventive care and lifestyle modifications. Healthcare providers are increasingly advocating for weight management, physical activity, and dietary adjustments as integral components of osteoarthritis management. This trend indicates a broader understanding of the disease, recognizing that holistic approaches can complement traditional medical interventions. As awareness of osteoarthritis continues to rise, stakeholders in the osteoarthritis market are likely to adapt their strategies to align with these emerging trends, ultimately aiming to enhance patient care and outcomes.

Rise in Non-Pharmacological Treatments

There is a noticeable shift towards non-pharmacological interventions in the osteoarthritis market. Patients and healthcare providers are increasingly recognizing the benefits of physical therapy, exercise programs, and dietary modifications. These approaches not only help manage symptoms but also promote overall joint health, potentially reducing the reliance on medications.

Technological Innovations in Treatment

The osteoarthritis market is witnessing a surge in technological advancements aimed at improving treatment efficacy. Innovations such as telemedicine, wearable devices, and mobile health applications are becoming integral to patient management. These technologies facilitate remote monitoring and personalized care, enhancing patient engagement and adherence to treatment plans.

Focus on Patient-Centric Care

There is a growing emphasis on patient-centric care within the osteoarthritis market. Healthcare providers are increasingly involving patients in decision-making processes regarding their treatment options. This trend reflects a broader movement towards personalized medicine, where therapies are tailored to individual patient needs and preferences, potentially leading to better health outcomes.

US Osteoarthritis Market Drivers

Rising Healthcare Expenditure

Healthcare expenditure in the United States continues to rise, which significantly impacts the osteoarthritis market. In 2023, healthcare spending reached approximately $4.3 trillion, with a substantial portion allocated to managing chronic conditions like osteoarthritis. This trend suggests that patients and healthcare providers are increasingly willing to invest in effective treatments, including medications, physical therapy, and surgical interventions. The financial commitment to managing osteoarthritis reflects the condition's impact on daily living and productivity. As healthcare costs continue to escalate, the osteoarthritis market is likely to see increased investment in research and development, leading to the introduction of new therapies and treatment modalities that address the needs of patients.

Increased Awareness and Education

There is a growing awareness and education surrounding osteoarthritis, which serves as a significant driver for the osteoarthritis market. Public health campaigns and educational initiatives have been instrumental in informing patients about the symptoms, risk factors, and available treatment options for osteoarthritis. This heightened awareness encourages individuals to seek medical advice and treatment earlier, potentially leading to better management of the condition. Furthermore, healthcare professionals are increasingly educated about the latest advancements in osteoarthritis management, which may influence treatment decisions. As awareness continues to expand, the demand for effective therapies and interventions in the osteoarthritis market is likely to increase, fostering innovation and development.

Growing Demand for Personalized Medicine

The trend towards personalized medicine is becoming increasingly relevant in the osteoarthritis market. Patients are seeking tailored treatment plans that consider their unique genetic, environmental, and lifestyle factors. This shift towards individualized care is driven by advancements in genetic research and technology, which enable healthcare providers to develop more effective treatment strategies. Personalized approaches may enhance treatment efficacy and patient satisfaction, as they align more closely with individual needs. As the demand for personalized medicine grows, the osteoarthritis market is likely to adapt, fostering innovation in treatment options and improving patient outcomes. This evolution may also encourage collaboration between researchers, clinicians, and pharmaceutical companies to develop targeted therapies.

Aging Population and Osteoarthritis Prevalence

The aging population in the United States is a primary driver of the osteoarthritis market. As individuals age, the likelihood of developing osteoarthritis increases significantly. Current estimates suggest that approximately 27 million adults in the US suffer from this condition, with the prevalence expected to rise as the population ages. By 2030, it is projected that nearly 67 million adults will be affected, indicating a growing demand for treatment options. This demographic shift necessitates advancements in the osteoarthritis market, as healthcare providers seek effective solutions to manage symptoms and improve quality of life for older adults. The increasing burden of osteoarthritis on healthcare systems further emphasizes the need for innovative therapies and interventions.

Advancements in Biologics and Regenerative Medicine

The osteoarthritis market is experiencing a surge in advancements related to biologics and regenerative medicine. These innovative treatment options, including stem cell therapy and platelet-rich plasma (PRP) injections, offer promising alternatives to traditional therapies. Research indicates that biologics may provide significant pain relief and improved joint function for osteoarthritis patients. As these therapies gain traction, they are likely to reshape treatment paradigms within the osteoarthritis market. The potential for biologics to address the underlying causes of osteoarthritis, rather than merely alleviating symptoms, could lead to a paradigm shift in how the condition is managed. This evolution in treatment options may attract investment and research funding, further propelling the market forward.

Market Segment Insights

By Type: Hip Osteoarthritis (Largest) vs. Spinal Osteoarthritis (Fastest-Growing)

In the US osteoarthritis market, Hip Osteoarthritis accounts for the largest share due to its widespread prevalence among aging populations. It represents a significant proportion of cases, driven by lifestyle factors and demographic trends. On the other hand, Spinal Osteoarthritis, while smaller in share, is rapidly gaining attention due to increasing awareness and diagnosis among patients. The growth for Spinal Osteoarthritis is attributed to factors such as the rise in sedentary lifestyles, leading to increased back issues, and a growing aging population more prone to spinal joint problems. Technological advancements in treatment options and heightened patient education have also contributed to its rapid development. The two segments highlight contrasting yet complementary trends within the market.

Hip Osteoarthritis (Dominant) vs. Spinal Osteoarthritis (Emerging)

Hip Osteoarthritis is characterized by degenerative changes that lead to severe pain and mobility issues, making it a dominant concern in the US osteoarthritis market. It primarily affects older adults but increasingly impacts younger individuals due to obesity and active lifestyles that stress joints. In contrast, Spinal Osteoarthritis is emerging as a significant segment, particularly as healthcare practitioners identify and address spinal joint disorders more effectively. This segment is evolving with new treatment modalities and educational measures aimed at improving patient outcomes, reflecting the changing focus of healthcare providers towards comprehensive osteoarthritis management.

By Diagnosis: Imaging (Largest) vs. Joint Fluid Analysis (Fastest-Growing)

In the US osteoarthritis market, the Diagnosis segment is largely dominated by Imaging techniques, which hold the largest market share. Imaging includes modalities such as X-rays and MRIs, essential for visualizing joint structures and assessing the extent of osteoarthritis. Joint Fluid Analysis, while smaller in market share, is gaining traction due to its ability to provide valuable biochemical information that can guide treatment decisions. The growth trends in the Diagnosis segment are driven by advancements in technology and increasing awareness of osteoarthritis among the population. With an aging demographic and rising obesity rates, the demand for accurate and efficient diagnostic techniques is at an all-time high. Joint Fluid Analysis is particularly poised for growth as healthcare providers seek to incorporate more comprehensive diagnostic methods that enhance patient management strategies.

Imaging (Dominant) vs. Joint Fluid Analysis (Emerging)

Imaging techniques such as X-rays and MRIs are the dominant force in the Diagnosis segment, providing critical insights for diagnosing osteoarthritis. These methods are well-established and widely accepted in clinical settings, involving minimal patient discomfort and allowing for detailed joint visualization. In contrast, Joint Fluid Analysis represents an emerging approach that offers unique insights by analyzing the synovial fluid. This technique is increasingly recognized for its potential to detect inflammatory markers and guide treatment. While Imaging remains the go-to method, the efficiency and rising utilization of Joint Fluid Analysis are contributing to its rapid market growth, as more healthcare providers emphasize personalized medicine in osteoarthritis treatment.

By Treatment: Medication (Largest) vs. Therapy (Fastest-Growing)

In the US osteoarthritis market, the treatment segment is segmented primarily into Medication, Surgery, and Therapy. Currently, Medication holds the largest market share due to its extensive use and acceptance among healthcare providers and patients alike, contributing significantly to its dominance. Surgery is also a crucial segment, but it does not compare in size to Medication. In contrast, Therapy is emerging rapidly, gaining traction as patients look for non-invasive and holistic approaches to manage symptoms and improve quality of life. Growth trends in the US osteoarthritis market show that there is an increasing preference for non-invasive treatments, with Therapy witnessing the fastest growth rate. This trend is driven by a rising awareness of the benefits of physical therapy and alternative treatment methods, alongside a growing demand for personalized treatment plans. Additionally, advancements in therapeutic techniques contribute to the expansion of this segment, appealing to patients seeking effective pain management solutions without the need for surgical intervention.

Medication: Dominant vs. Therapy: Emerging

Medication remains the dominant player in the US osteoarthritis market, characterized by a wide array of options, including analgesics and anti-inflammatory drugs. Its strong presence is attributed to established clinical practices and recommendations from healthcare professionals. Patients often rely on these medications for immediate pain relief and symptomatic management, making it a go-to choice. Conversely, Therapy, which includes physical therapy and other innovative interventions, is considered an emerging segment. It is becoming increasingly popular among patients as they seek alternatives to traditional medications. Therapy not only helps alleviate pain but also focuses on enhancing mobility and overall well-being. The shift towards non-invasive treatments is shaping the landscape, with Therapy expected to witness robust growth in the coming years.

By End User: Hospitals (Largest) vs. Medical Institutes (Fastest-Growing)

In the US osteoarthritis market, the end user segment is primarily dominated by hospitals, which hold the largest share. Hospitals capture a significant portion of the market due to their extensive infrastructure, advanced treatment options, and comprehensive patient care services. Medical institutes, while smaller in market share, are emerging as important players, particularly in research and specialized treatment programs. Their ability to innovate and provide targeted therapies makes them vital to the sector. Growth trends within the end user segment are primarily driven by an increasing prevalence of osteoarthritis and a rising demand for effective treatment options. Hospitals are expanding their facilities and enhancing their service offerings, focusing on improving patient outcomes. Simultaneously, medical institutes are gaining traction for their research capabilities and specialized approach to treatment, positioning them as the fastest-growing segment. The collaboration between these two segments is also fostering innovation in the market.

Hospitals: Dominant vs. Medical Institutes: Emerging

Hospitals are the dominant players in the US osteoarthritis market, equipped with the necessary resources and capabilities to handle a large influx of patients. They offer a wide range of treatments, including surgical options and rehabilitation services, thereby ensuring comprehensive patient management. Their established infrastructure allows for the implementation of advanced technologies and personalized treatment plans. On the other hand, medical institutes are emerging as significant contributors, particularly in the development of innovative therapies and clinical research. They focus on niche areas and often lead advancements in osteoarthritis management, appealing to patients seeking specialized care. This dynamic between hospitals and medical institutes is crucial, as it drives growth and enhances the overall effectiveness of treatments available in the market.

Get more detailed insights about US Osteoarthritis Market

Request Free Sample

Key Players and Competitive Insights

The osteoarthritis market exhibits a dynamic competitive landscape characterized by a blend of innovation, strategic partnerships, and a focus on patient-centric solutions. Key players such as Johnson & Johnson (US), AbbVie Inc. (US), and Eli Lilly and Company (US) are actively shaping the market through their distinct operational strategies. Johnson & Johnson (US) emphasizes innovation in its product pipeline, particularly in biologics and disease-modifying osteoarthritis drugs (DMOADs), while AbbVie Inc. (US) focuses on expanding its portfolio through strategic acquisitions and collaborations. Eli Lilly and Company (US) is leveraging digital health technologies to enhance patient engagement and treatment adherence, indicating a shift towards more integrated care models. Collectively, these strategies contribute to a competitive environment that prioritizes advanced therapeutic options and patient outcomes. The business tactics employed by these companies reflect a concerted effort to optimize supply chains and localize manufacturing processes. The market structure appears moderately fragmented, with several players vying for market share while also collaborating on research and development initiatives. This collective influence of key players fosters a competitive atmosphere where innovation and operational efficiency are paramount. In October 2025, Johnson & Johnson (US) announced a partnership with a leading digital health company to develop a mobile application aimed at improving patient monitoring and treatment adherence for osteoarthritis. This strategic move underscores the company's commitment to integrating technology into its therapeutic offerings, potentially enhancing patient outcomes and engagement. The collaboration may also position Johnson & Johnson (US) as a frontrunner in the digital health space within the osteoarthritis market. In September 2025, AbbVie Inc. (US) completed the acquisition of a biotech firm specializing in regenerative medicine, which is expected to bolster its capabilities in developing innovative therapies for osteoarthritis. This acquisition not only expands AbbVie’s product pipeline but also aligns with its strategy to enhance its position in the regenerative medicine sector. The integration of advanced technologies from the acquired firm could lead to breakthroughs in treatment options, thereby strengthening AbbVie’s competitive edge. In August 2025, Eli Lilly and Company (US) launched a new initiative focused on artificial intelligence (AI) to streamline clinical trials for osteoarthritis treatments. This initiative aims to reduce the time and cost associated with drug development, potentially accelerating the introduction of new therapies to the market. By harnessing AI, Eli Lilly and Company (US) is likely to enhance its research capabilities, thereby positioning itself as a leader in innovative drug development. As of November 2025, current competitive trends in the osteoarthritis market are increasingly defined by digitalization, sustainability, and the integration of AI technologies. Strategic alliances among key players are shaping the landscape, fostering collaboration that enhances research and development efforts. Looking ahead, competitive differentiation is expected to evolve, with a notable shift from price-based competition towards innovation, technological advancements, and supply chain reliability. This transition may ultimately lead to improved patient outcomes and a more sustainable market environment.

Key Companies in the US Osteoarthritis Market include

Future Outlook

US Osteoarthritis Market Future Outlook

The Osteoarthritis Market is projected to grow at a 9.12% CAGR from 2025 to 2035, driven by increasing prevalence, advancements in treatment options, and rising healthcare expenditure.

New opportunities lie in:

Development of telehealth platforms for remote patient monitoring and consultations. Investment in regenerative medicine technologies, such as stem cell therapies. Expansion of personalized treatment plans utilizing genetic profiling for tailored therapies.

By 2035, the osteoarthritis market is expected to achieve substantial growth, reflecting evolving treatment paradigms and increased patient demand.

Market Segmentation

US Osteoarthritis Market Type Outlook

Hip Osteoarthritis
Spinal Osteoarthritis

US Osteoarthritis Market End User Outlook

Hospitals
Medical Institutes

US Osteoarthritis Market Diagnosis Outlook

Imaging
Joint Fluid Analysis

US Osteoarthritis Market Treatment Outlook

Medication
Surgery
Therapy

Report Scope

MARKET SIZE 2024	895.6(USD Million)
MARKET SIZE 2025	977.28(USD Million)
MARKET SIZE 2035	2339.22(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR)	9.12% (2025 - 2035)
REPORT COVERAGE	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR	2024
Market Forecast Period	2025 - 2035
Historical Data	2019 - 2024
Market Forecast Units	USD Million
Key Companies Profiled	Johnson & Johnson (US), Pfizer Inc. (US), Boehringer Ingelheim (DE), Novartis AG (CH), AbbVie Inc. (US), Amgen Inc. (US), Sanofi (FR), GlaxoSmithKline (GB), Eli Lilly and Company (US)
Segments Covered	Type, Diagnosis, Treatment, End User
Key Market Opportunities	Advancements in personalized medicine and digital therapeutics enhance treatment options in the osteoarthritis market.
Key Market Dynamics	Rising demand for innovative therapies drives competition and regulatory scrutiny in the osteoarthritis market.
Countries Covered	US

FAQs

What was the overall valuation of the US osteoarthritis market in 2024?

The overall market valuation was $895.6 Million in 2024.

What is the projected market valuation for the US osteoarthritis market by 2035?

The projected valuation for 2035 is $2339.22 Million.

What is the expected CAGR for the US osteoarthritis market during the forecast period 2025 - 2035?

The expected CAGR for the market during this period is 9.12%.

Which companies are considered key players in the US osteoarthritis market?

Key players include Johnson & Johnson, Pfizer Inc., Boehringer Ingelheim, Novartis AG, AbbVie Inc., Amgen Inc., Sanofi, GlaxoSmithKline, and Eli Lilly and Company.

What are the market segments for the US osteoarthritis market?

The market segments include Type, Diagnosis, Treatment, and End User.

What was the valuation for hip osteoarthritis in 2024?

The valuation for hip osteoarthritis was $358.56 Million in 2024.

What is the projected valuation for spinal osteoarthritis by 2035?

The projected valuation for spinal osteoarthritis by 2035 is $1389.61 Million.

What are the projected valuations for imaging and joint fluid analysis in 2035?

The projected valuations are $1000.0 Million for imaging and $1339.22 Million for joint fluid analysis.

What was the valuation for medication treatment in 2024?

The valuation for medication treatment was $350.0 Million in 2024.

What is the projected valuation for hospitals as an end user by 2035?

The projected valuation for hospitals as an end user by 2035 is $1395.22 Million.

Author

Author

Nidhi Mandole

Senior Research Analyst

She is an extremely curious individual currently working in Healthcare and Medical Devices Domain. Nidhi is comfortably versed in data centric research backed by healthcare educational background. She leverages extensive data mining and analytics tools such as Primary and Secondary Research, Statistical Analysis, Machine Learning, Data Modelling. Her key role also involves Technical Sales Support, Client Interaction and Project management within the Healthcare team. Lastly, she showcases extensive affinity towards learning new skills and remain fascinated in implementing them.

Co-Author

Garvit Vyas

Vice President - Operations

Garvit Vyas is a Research Analyst with experience in working across multiple industry domains in the market research sector. Over the past four years, he has been actively involved in analyzing diverse markets, gathering industry insights, and contributing to the development of comprehensive research reports. His work includes studying market trends, evaluating competitive landscapes, and supporting data-driven business insights. In the early phase of his career, Garvit worked on cross-domain research projects, which helped him build a strong foundation in market analysis, data interpretation, and industry intelligence across various sectors. Later, he transitioned into the Quality Control (QC) function, where he focuses on reviewing and refining research reports and marketing collaterals to ensure accuracy, consistency, and high editorial standards. His responsibilities include validating research data, improving report structure, and maintaining the overall quality of published content. Garvit is committed to maintaining strong research integrity and delivering reliable insights that support informed business decision-making.

Get In Touch

Leave a Comment